Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Checkpoint Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD300C drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD300C ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CD300C Products |
| Gene Delivery | CD300C Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based binding assays. |
View CD300C Products |
| Benchmark Ab | Anti-CD300C Benchmark Antibody Recombinant positive control derived from clinical-stage/validated sequences. |
View CD300C Products |
| Validator | CD300C siRNA Set For target knockdown and specificity verification in primary myeloid cells. |
View CD300C Products |
| Related Target A | CD300A Inhibitory homolog of CD300C. Essential for negative selection and specificity screening. |
View CD300A Products |
| Related Target B | CD300E Myeloid-associated CD300 family member. Crucial for subfamily cross-reactivity profiling. |
View CD300E Products |
| Related Target C | TIM-3 Co-inhibitory receptor sharing phosphatidylserine (PS) binding characteristics. |
View TIM3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Off-Target Binding (CD300a cross-reactivity) | High-purity CD300A and CD300C ECD proteins strictly verified by Mass Spectrometry for sequence fidelity. |
| Loss of Native Conformation in Cell Assays | Lentiviral transduction particles for stable overexpression on human myeloid host cells, preserving native folding. |
| Lack of Controls | Sequence-verified Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives in Knockdown Studies | Validated siRNA pool included for target-specific gene knockdown and functional verification. |
Live CD300C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD300C therapeutics is intensifying, with major players shifting focus from traditional T-cell checkpoints to myeloid-derived immune checkpoints. As first-generation therapies targeting PD-1/PD-L1 encounter resistance, the next wave of R&D is targeting CD300C to modulate the immunosuppressive microenvironment of solid tumors and acute myeloid leukemia (AML).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Biotech Innovators, Academic Medical Centers | Solid Tumors, AML | Epitope mapping & high-affinity binding (Requires HEK293-expressed CD300C ECD-Fc) |
| Bispecific Antibody | Immuno-oncology Therapeutics Developers | Refractory Lymphomas, Solid Tumors | Heterodimer validation & dual-targeting assays (Requires CD300C and CD300A cross-reactivity screening) |
| Small Molecule / Inhibitors | Pharmaceutical R&D Divisions | Myelodysplastic Syndromes (MDS) | High-throughput screening & target engagement (Requires stable cell line construction via Lentivirus) |